Earlier, analysis of a limited amount of ceramides showed that increased Cer[NS] and decreased Cer[EOS] abundances in the skin of patients with AD normalized towards the level of controls during dupilumab treatment (80, 81). The gene discussed is CBLN1; the disease is Alzheimer disease.